Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DDR2 | Q16832 | 9/20 | 0.36 |
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | ITK | Q08881 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572431 | 1.00 | GSK3B (0.37) | GSK3BDYRK1ADDR2BRAFITK | |
| SCHEMBL1573257 | 0.92 | GSK3B (0.35) | GSK3BDYRK1ADDR2BRAFITK | |
| SCHEMBL1573258 | 0.92 | GSK3B (0.35) | GSK3BDYRK1ADDR2BRAFITK | |
| SCHEMBL3504727 | 0.91 | BRAF (0.37) | DDR2BRAFEGFRRAF1 | |
| SCHEMBL1867129 | 0.91 | GSK3B (0.35) | GSK3BDYRK1ADDR2BRAFITK | |
| SCHEMBL1867131 | 0.91 | GSK3B (0.35) | GSK3BDYRK1ADDR2BRAFITK | |
| SCHEMBL1570912 | 0.88 | BRAF (0.36) | DDR2BRAFEGFRRAF1 | |
| SCHEMBL1570909 | 0.88 | BRAF (0.36) | DDR2BRAFEGFRRAF1 | |
| SCHEMBL1872111 | 0.87 | BRAF (0.36) | DDR2BRAFEGFRRAF1 | |
| SCHEMBL1571553 | 0.87 | BRAF (0.36) | DDR2BRAFEGFRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | GSK3B 406/4885DYRK1A 748/4885DDR2 1418/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | GSK3B 340/4885DYRK1A 1286/4885DDR2 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.